U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21N
Molecular Weight 275.3874
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOBENZAPRINE

SMILES

CN(C)CCC=C1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

InChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/slideshow/flexeril-cyclobenzaprine-muscle-relaxants-1266 | http://www.rxlist.com/flexeril-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/26926618 | https://www.ncbi.nlm.nih.gov/pubmed/26668287

Cyclobenzaprine is a centrally-acting muscle relaxant which boosts levels of norepinephrine and binds to serotonin receptors in the brain to reduce spasm. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Drowsiness, fatigue and sedation (up to 40%) is the most common side effect of Cyclobenzaprine. It may have life-threatening interactions with monoamine oxidase (MAO) inhibitors. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.

CNS Activity

Originator

Approval Year

1977
44
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Substrate
661
Substrate
661
Substrate
661
Inhibitor
8297
 3.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
CYCLOBENZAPRINE HYDROCHLORIDE

Approved Use

Drug is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.3 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/19243711
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
354.1 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/19243711
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
33.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/19243711
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
Disc. AE: Lethargy, Slurred speech...
AEs leading to
discontinuation/dose reduction:
Lethargy
Slurred speech
Sinus tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
Disc. AE: Sinus tachycardia, Confusion...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia
Confusion
Drowsiness
Agitation
Visual hallucinations
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
Page: p.1068
unhealthy, 41.5
n = 249
Health Status: unhealthy
Condition: Muscle spasm
Age Group: 41.5
Sex: M+F
Population Size: 249
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
Page: p.1068
Disc. AE: Somnolence...
AEs leading to
discontinuation/dose reduction:
Somnolence (5.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
Page: p.1068
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
Disc. AE: Serotonin syndrome, Cardiovascular disorder NOS...
AEs leading to
discontinuation/dose reduction:
Serotonin syndrome (grade 4)
Cardiovascular disorder NOS
CNS depression
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Other AEs: Tachycardia, Dry mouth...
Other AEs:
Tachycardia (below serious, 1 patient)
Dry mouth (below serious, 6 patients)
Toothache (below serious, 1 patient)
Rhinitis (below serious, 1 patient)
Dizziness (below serious, 1 patient)
Dysgeusia (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Disruptive mood dysregulation disorder (below serious, 1 patient)
Sleep disorder (below serious, 1 patient)
Somnolence (below serious, 18 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
AEs

AEs

AESignificanceDosePopulation
Lethargy Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
Sinus tachycardia Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
Slurred speech Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.282
Agitation Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
Confusion Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
Drowsiness Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
Sinus tachycardia Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
Visual hallucinations Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6620442
Page: p.283
Somnolence 5.2%
Disc. AE
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
Page: p.1068
unhealthy, 41.5
n = 249
Health Status: unhealthy
Condition: Muscle spasm
Age Group: 41.5
Sex: M+F
Population Size: 249
Sources:
https://pubmed.ncbi.nlm.nih.gov/12809957
Page: p.1068
CNS depression Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
Cardiovascular disorder NOS Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
Serotonin syndrome grade 4
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf
Page: p.1
Anxiety below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Disruptive mood dysregulation disorder below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Dizziness below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Dysgeusia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Rhinitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Sleep disorder below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Tachycardia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Toothache below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Somnolence below serious, 18 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Dry mouth below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
https://clinicaltrials.gov/ct2/show/NCT02814565
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
substrate
1217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1054

UGT1A4
347

UGT2B10
127
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1217
 minor
CYP1A2
1054
 yes
CYP3A4
1737
 yes
UGT1A4
347
 yes
UGT2B10
127
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3996
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3996
ZINC
ZINC000000968263
http://zinc15.docking.org/substances/ZINC000000968263
PubMed

PubMed

TitleDatePubMed
The control of impurities in amitriptyline hydrochloride using a reversed-phase hybrid stationary phase.
2005 Aug
Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.
2006 Dec
Shift work and pathological conditions.
2006 Dec 11
Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity.
2006 Jul 17
Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study.
2006 Nov 16
Extended-release cyclobenzaprine (Amrix).
2007 Dec 17
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Do motor control genes contribute to interindividual variability in decreased movement in patients with pain?
2007 Jul 26
Interpreting tricyclic antidepressant measurements in urine in an emergency department setting: comparison of two qualitative point-of-care urine tricyclic antidepressant drug immunoassays with quantitative serum chromatographic analysis.
2007 Jun
An internet survey of 2,596 people with fibromyalgia.
2007 Mar 9
Inappropriate prescribing in an older ED population.
2007 Sep
Characteristics and healthcare costs of patients with fibromyalgia syndrome.
2007 Sep
Endoscopic findings in loin pain hematuria syndrome: concentric clot in calyceal fornices.
2008
Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study.
2008
A meta-analysis of the efficacy of fibromyalgia treatment according to level of care.
2008
Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial.
2008
Treatment options and patient perspectives in the management of fibromyalgia: future trends.
2008 Dec
Newer treatments for fibromyalgia syndrome.
2008 Dec
Anticholinergic esotropia.
2008 Dec
Rasagiline in treatment of Parkinson's disease.
2008 Feb
Skeletal muscle relaxants.
2008 Feb
Lower facial contouring with botulinum toxin type A.
2008 Nov
Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report.
2008 Nov
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.
2008 Nov 30
Elderly patient refractory to multiple pain medications successfully treated with integrative East-West medicine.
2008 Nov 30
Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles.
2009
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
2009
Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study.
2009
Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study.
2009
Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability.
2009 Apr
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
2009 Apr 28
Plasmapheresis in a patient with rhabdomyolysis: a case report.
2009 Aug 12
A 19-month-old girl with recurrent illness: over the hills and through the woods.
2009 Dec
A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
2009 Jan
Rhabdomyolysis associated with the nutritional supplement Hydroxycut.
2009 Jan 15
Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design.
2009 May
Standardized natural product cannabis in pain management and observations at a Canadian compassion society: a case report.
2009 May 18
Fibromyalgia and myofascial pain syndrome-a dilemma.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Electroencephalographic correlates of Chronic Fatigue Syndrome.
2009 Oct 6
Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study.
2009 Oct 7
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.
2010 Apr 7
Comparison of ibuprofen, cyclobenzaprine or both in patients with acute cervical strain: a randomized controlled trial.
2010 Jan
Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis.
2010 Jul
Pharmacologic management of chronic pain.
2010 Jun
Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity.
2010 Jun 30
Case files of the California poison control system, San Francisco division: blue thunder ingestion: methanol, nitromethane, and elevated creatinine.
2010 Mar
Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry.
2010 Mar
Impact of poor-quality medicines in the 'developing' world.
2010 Mar
Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.
2010 Nov
Patents

Patents

GB858187
2
JP2006505569A
69
JP4763957B2
87

Sample Use Guides

In Vivo Use Guide
5 mg three times a day. Based on individual patient response, the dose may be increased to either 7.5 mg or 10 mg three times a day.
Route of Administration: Oral
In Vitro Use Guide
The iontaphoretic application of Cyclobenzaprine (CBZ) caused, in all cases, a decrease in discharge rate. This slowing was invariably attended by a marked decrease in action potential amplitude however, and was therefore considered likely to be a local anesthetic effect, even at 5 nA. On the other hand, when CBZ was infused into the chamber to a concentration equivalent to 1 mg/kg for the whole animal, assuming distribution in all extracellular water, all cells responded and no local anesthetic effects were evident. The six cells with initial discharge rates between 2 and 10 Hz decreased firing with CBZ, whereas the four cells with initial rates between 0.5 and 1.5 Hz increased their rates with CBZ.
Name Type Language
CYCLOBENZAPRINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CYCLOBENZAPRINE [MI]
Common Name English
MK-130 (AS THE BASE)
Code English
Cyclobenzaprine [WHO-DD]
Common Name English
MK-130
Systematic Name English
cyclobenzaprine [INN]
Common Name English
CYCLOBENZAPRINE [VANDF]
Common Name English
CYCLOBENZAPRINE [USP IMPURITY]
Common Name English
N,N-DIMETHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-(SUP .DELTA.5,.GAMMA.)-PROPYLAMINE
Common Name English
TNX-102
Code English
AMITRIPTYLINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
NORTRIPTYLINE HYDROCHLORIDE IMPURITY E [EP IMPURITY]
Common Name English
1-PROPANAMINE, 3-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-
Systematic Name English
3-(5H-DIBENZO(A,D)(7)ANNULEN-5-YLIDENE)-N,N-DIMETHYLPROPAN-1-AMINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29696
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
NDF-RT N0000175737
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
NDF-RT N0000175730
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
WHO-VATC QM03BX08
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
LIVERTOX NBK548894
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
WHO-ATC M03BX08
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
Code System Code Type Description
LACTMED
Cyclobenzaprine
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
EVMPD
SUB06849MIG
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
FDA UNII
69O5WQQ5TI
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
DRUG CENTRAL
751
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
WIKIPEDIA
CYCLOBENZAPRINE
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-145-8
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL669
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
MERCK INDEX
m3976
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY Merck Index
IUPHAR
7152
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
SMS_ID
100000083730
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
DRUG BANK
DB00924
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
CAS
303-53-7
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
HSDB
8305
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
INN
791
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
MESH
C004704
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
NCI_THESAURUS
C28947
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
CHEBI
3996
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
DAILYMED
69O5WQQ5TI
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
RXCUI
21949
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY RxNorm
PUBCHEM
2895
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046933
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of CYCLOBENZAPRINE
METABOLITE (PARENT)
Structure of 3-HYDROXYCYCLOBENZAPRINE
METABOLITE (PARENT)
Structure of CYCLOBENZAPRINE EPOXIDE
METABOLITE (PARENT)
Structure of 2-HYDROXYCYCLOBENZAPRINE
METABOLITE (PARENT)
Structure of NORCYCLOBENZAPRINE
METABOLITE (PARENT)
Structure of CYCLOBENZAPRINE N-OXIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966